{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:12:09Z","timestamp":1790507529802,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11899-018-0436-z","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T05:29:00Z","timestamp":1520400540000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Update on the Treatment of Anaplastic Large Cell Lymphoma"],"prefix":"10.1007","volume":"13","author":[{"given":"Khoan","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"436_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","volume":"126","author":"G Hapgood","year":"2015","unstructured":"Hapgood G, Savage KJ. Review article the biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126:17\u201326. Available from: http:\/\/www.bloodjournal.org\/content\/126\/1\/17.abstract%5Cn . http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25869285","journal-title":"Blood"},{"key":"436_CR2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science. 1994;263:1281\u20134. [cited 2017 Sep 14], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8122112","journal-title":"Science"},{"key":"436_CR3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790\u20135. https:\/\/doi.org\/10.1002\/ajh.24086 .","journal-title":"Am J Hematol"},{"key":"436_CR4","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558 .","journal-title":"J Clin Oncol"},{"key":"436_CR5","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496\u2013504. [cited 2017 Oct 1], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18385450","journal-title":"Blood"},{"key":"436_CR6","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","volume":"30","author":"D Sibon","year":"2012","unstructured":"Sibon D, Fournier M, Bri\u00e8re J, Lamant L, Haioun C, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials. J Clin Oncol. 2012;30:3939\u201346. https:\/\/doi.org\/10.1200\/JCO.2012.42.2345 .","journal-title":"J Clin Oncol"},{"key":"436_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","volume":"117","author":"AL Feldman","year":"2011","unstructured":"Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117:915\u20139. https:\/\/doi.org\/10.1182\/blood-2010-08-303305 .","journal-title":"Blood"},{"key":"436_CR8","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","volume":"120","author":"G Vasmatzis","year":"2012","unstructured":"Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120:2280\u20139. https:\/\/doi.org\/10.1182\/blood-2012-03-419937 .","journal-title":"Blood"},{"key":"436_CR9","first-page":"1473","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood [Internet] Am Soc Hematol. 2014;124:1473\u201380. [cited 2017 Oct 2], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24894770","journal-title":"Blood [Internet] Am Soc Hematol"},{"key":"436_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/cup.12937","volume":"44","author":"RA Brown","year":"2017","unstructured":"Brown RA, Fernandez-Pol S, Kim J. Primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol. 2017;44:570\u20137. [cited 2017 Sep 14], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28342276","journal-title":"J Cutan Pathol"},{"key":"436_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","volume":"49","author":"HL Liu","year":"2003","unstructured":"Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049\u201358. [cited 2017 Sep 14], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14639383","journal-title":"J Am Acad Dermatol"},{"key":"436_CR12","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","volume":"95","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653\u201361. [cited 2017 Oct 8], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10845893","journal-title":"Blood"},{"key":"436_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1610-0387.2011.07794.x","volume":"10","author":"N Booken","year":"2012","unstructured":"Booken N, Goerdt S, Klemke C-D. Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry. J Dtsch Dermatol. 2012;10:331\u20139. https:\/\/doi.org\/10.1111\/j.1610-0387.2011.07794.x .","journal-title":"J Dtsch Dermatol"},{"key":"436_CR14","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","volume":"118","author":"W Kempf","year":"2011","unstructured":"Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024\u201335. https:\/\/doi.org\/10.1182\/blood-2011-05-351346 .","journal-title":"Blood"},{"key":"436_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"\u2022\u2022 Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet (Lond Engl). 2017;390:555\u201366. [cited 2017 Oct 22], Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673617312667 . Potentially practice-changing data in CD30-positive cutaneous T-cell lymphoma treated with brentuximab veodotin.","journal-title":"Lancet (Lond Engl)"},{"key":"436_CR16","doi-asserted-by":"publisher","unstructured":"Leberfinger AN, Behar BJ, Williams NC, Rakszawski KL, Potochny JD, Mackay DR, et al. Breast implant\u2013associated anaplastic large cell lymphoma. JAMA Surg. 2017;17033. https:\/\/doi.org\/10.1001\/jamasurg.2017.4026 .","DOI":"10.1001\/jamasurg.2017.4026"},{"key":"436_CR17","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.ejso.2017.05.004","volume":"43","author":"L Johnson","year":"2017","unstructured":"Johnson L, O\u2019Donoghue JM, McLean N, Turton P, Khan AA, Turner SD, et al. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. Eur J Surg Oncol. 2017;43:1393\u2013401. [cited 2017 Nov 24], Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879831730481X","journal-title":"Eur J Surg Oncol"},{"key":"436_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","volume":"32","author":"RN Miranda","year":"2014","unstructured":"Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant\u2013associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32:114\u201320. [cited 2017 Sep 14], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24323027","journal-title":"J Clin Oncol"},{"key":"436_CR19","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418\u201325. https:\/\/doi.org\/10.1182\/blood-2010-02-270785 .","journal-title":"Blood"},{"key":"436_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151:159\u201366. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08329.x .","journal-title":"Br J Haematol"},{"key":"436_CR21","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escal\u00f3n","year":"2005","unstructured":"Escal\u00f3n MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005;103:2091\u20138. https:\/\/doi.org\/10.1002\/cncr.20999 .","journal-title":"Cancer"},{"key":"436_CR22","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:2211\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdu443 .","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"436_CR23","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.40.2719 .","journal-title":"J Clin Oncol"},{"key":"436_CR24","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1038\/bcj.2016.63","volume":"6","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452. [cited 2017 Oct 1], Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27471868","journal-title":"Blood Cancer J"},{"key":"436_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ejh.12060","volume":"90","author":"X-M Zhang","year":"2013","unstructured":"Zhang X-M, Li Y-X, Wang W-H, Jin J, Wang S-L, Liu Y-P, et al. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma. Eur J Haematol. 2013;90:195\u2013201. https:\/\/doi.org\/10.1111\/ejh.12060 .","journal-title":"Eur J Haematol"},{"key":"436_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.critrevonc.2013.08.016","volume":"89","author":"M Gkotzamanidou","year":"2014","unstructured":"Gkotzamanidou M, Papadimitriou CA. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Crit Rev Oncol Hematol. 2014;89:248\u201361. [cited 2017 Sep 17], Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813001935","journal-title":"Crit Rev Oncol Hematol"},{"key":"436_CR27","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.bbmt.2011.02.008","volume":"17","author":"A Nademanee","year":"2011","unstructured":"Nademanee A, Palmer JM, Popplewell L, Tsai N-C, Delioukina M, Gaal K, et al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. Biol Blood Marrow Transplant. 2011;17:1481\u20139. [cited 2017 Sep 24], Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111001029","journal-title":"Biol Blood Marrow Transplant"},{"key":"436_CR28","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","volume":"22","author":"ED Jacobsen","year":"2011","unstructured":"Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome. Ann Oncol Off J Eur Soc Med Oncol. 2011;22:1608\u201313. https:\/\/doi.org\/10.1093\/annonc\/mdq698 .","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"436_CR29","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Gouill Le","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant J-P, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire. J Clin Oncol. 2008;26:2264\u201371. https:\/\/doi.org\/10.1200\/JCO.2007.14.1366 .","journal-title":"J Clin Oncol"},{"key":"436_CR30","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23897963","journal-title":"J Clin Oncol"},{"key":"436_CR31","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172\u20136. https:\/\/doi.org\/10.1200\/JCO.2004.12.050 .","journal-title":"J Clin Oncol"},{"key":"436_CR32","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1002965 .","journal-title":"N Engl J Med"},{"key":"436_CR33","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.38.0402 .","journal-title":"J Clin Oncol"},{"key":"436_CR34","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;blood-2017-05-780049. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28974506 ."},{"key":"436_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","volume":"7","author":"NL Bartlett","year":"2014","unstructured":"Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24. https:\/\/doi.org\/10.1186\/1756-8722-7-24 .","journal-title":"J Hematol Oncol"},{"key":"436_CR36","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"\u2022 Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137\u201343. https:\/\/doi.org\/10.1200\/JCO.2013.54.2456 . Potentially practice-changing data in CD30-positive peripheral T-cell lymphomas which form the basis of the ongoing ECHELON-2 phase 3 trial comparing standard CHOP to combination CHP plus BV in newly diagnosed CD30+ PTCLs.","journal-title":"J Clin Oncol"},{"key":"436_CR37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21245435","journal-title":"J Clin Oncol"},{"key":"436_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22271479","journal-title":"J Clin Oncol"},{"key":"436_CR39","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26101246","journal-title":"J Clin Oncol"},{"key":"436_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMc1013224","volume":"364","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364:775\u20136. https:\/\/doi.org\/10.1056\/NEJMc1013224 .","journal-title":"N Engl J Med"},{"key":"436_CR41","doi-asserted-by":"publisher","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","volume":"106","author":"C Gambacorti Passerini","year":"2014","unstructured":"Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106:djt378. https:\/\/doi.org\/10.1093\/jnci\/djt378 .","journal-title":"J Natl Cancer Inst"},{"key":"436_CR42","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698\u2013704. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27269947","journal-title":"J Clin Oncol"},{"key":"436_CR43","doi-asserted-by":"crossref","unstructured":"Ansell S, Gutierrez ME, Shipp MA, Gladstone D, Moskowitz A, Borello I, Popa-Mckiver M, Farsaci B, Zhu L, Lesokhin AM, Arman P. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016;128. Available from: http:\/\/www.bloodjournal.org\/content\/128\/22\/183 .","DOI":"10.1182\/blood.V128.22.183.183"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-018-0436-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0436-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-018-0436-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T01:51:58Z","timestamp":1603936318000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-018-0436-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s11899-018-0436-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"7 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they do not have conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}